Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies

Neuroimaging (DJ Brooks, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuroimaging


Cognitive impairment and dementia are significant sequelae of Parkinson disease (PD) and comprise a key feature of dementia with Lewy bodies (DLB), a disease with similar clinical and neuropathological features. Multiple independent causes have been implicated in PD dementia (PDD) and DLB, among them the accumulation of β-amyloid, a neuropathological hallmark of Alzheimer disease. Over the last decade, PET imaging has emerged as a viable method to measure amyloid burden in the human brain and relate it to neurodegenerative diseases. This article reviews what amyloid imaging has taught us about PDD and DLB. Current data suggest that brain amyloid deposition tends to be more marked in DLB, yet contributes to cognitive impairment in both DLB and PD. These results are broadly consistent with neuropathology and CSF studies. β-Amyloid may interact synergistically with other pathological processes in PD and DLB to contribute to cognitive impairment.


Amyloid Pittsburgh compound B Parkinson disease dementia Dementia with Lewy bodies PET 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedGoogle Scholar
  2. 2.
    Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.PubMedGoogle Scholar
  3. 3.
    Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598–606.PubMedGoogle Scholar
  4. 4.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630–45.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010;74:77–84.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ, et al. Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging. 2012;33:878–85.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365–71.PubMedGoogle Scholar
  8. 8.
    Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086–92.PubMedGoogle Scholar
  9. 9.
    Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229–34.PubMedGoogle Scholar
  10. 10.
    Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431–4.PubMedGoogle Scholar
  11. 11.
    Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.PubMedGoogle Scholar
  12. 12.
    Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122–31.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2009;80:998–1001.PubMedGoogle Scholar
  14. 14.
    Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39:619–33.PubMedGoogle Scholar
  15. 15.
    Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.PubMedGoogle Scholar
  16. 16.
    Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305:275–83.PubMedGoogle Scholar
  18. 18.
    Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9.PubMedGoogle Scholar
  19. 19.
    Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.PubMedGoogle Scholar
  20. 20.
    Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, et al. Florbetapir F-18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med. 2011;41:300–4.PubMedGoogle Scholar
  21. 21.
    Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.PubMedGoogle Scholar
  22. 22.
    Wong DF, Moghekar AR, Rigamonti D, Brašić JR, Rousset O, Willis W, et al. An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol. 2013;15:230–7.PubMedCentralPubMedGoogle Scholar
  23. 23.•
    Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7. Florbetaben was used to assess and compare amyloid burden in AD subjects, DLB subjects, PD subjects, FTD subjects, vascular dementia subjects, and HCS, and demonstrated results similar to those obtained with PiB.PubMedGoogle Scholar
  24. 24.•
    Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Alzheimer’s Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014. doi:10.1007/s00259-014-2753-3. This article showed high correlation in PET characteristics among PiB, florbetapir, and flutemetamol.PubMedGoogle Scholar
  25. 25.
    Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63.PubMedGoogle Scholar
  26. 26.
    Smid LM, Vovko TD, Popovic M, Petric A, Kepe V, Barrio JR, et al. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol. 2006;16:124–30.PubMedGoogle Scholar
  27. 27.
    Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903–10.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–17.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83.PubMedGoogle Scholar
  30. 30.
    Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, et al. APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology. 2012;78:232–40.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, et al. Aβ amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement. 2013;9:538–45.PubMedGoogle Scholar
  33. 33.
    Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013;80:1341–8.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636–44.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014. doi:10.1038/mp.2014.9.PubMedGoogle Scholar
  36. 36.
    Ossenkoppele R, van der Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 2014;82:1768–75.PubMedGoogle Scholar
  37. 37.
    Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol. 2003;25:94–109.PubMedGoogle Scholar
  39. 39.
    Mortimer JA, Pirozzolo FJ, Hansch EC, Webster DD. Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology. 1982;32:133–7.PubMedGoogle Scholar
  40. 40.
    Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26:1814–24.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender Arch Neurol. 1992;49:492–7.Google Scholar
  42. 42.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387–92.PubMedGoogle Scholar
  43. 43.
    Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707.PubMedGoogle Scholar
  44. 44.
    McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.PubMedGoogle Scholar
  45. 45.
    Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.PubMedGoogle Scholar
  46. 46.
    Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol. 1989;26:47–50.PubMedGoogle Scholar
  47. 47.
    Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407–11.PubMedGoogle Scholar
  48. 48.
    Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord. 2013;28:697–701.PubMedGoogle Scholar
  49. 49.
    Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kövari E. Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord. 2013;19:864–8.PubMedGoogle Scholar
  50. 50.
    Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102:355–63.PubMedGoogle Scholar
  51. 51.
    Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72:587–98.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66–79.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010;120:131–43.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014;29:634–50.PubMedGoogle Scholar
  55. 55.
    Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115:427–36.PubMedGoogle Scholar
  56. 56.
    Kövari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull. 2009;80:203–10.PubMedGoogle Scholar
  57. 57.
    Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ, et al. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2013;72:1203–12.PubMedGoogle Scholar
  58. 58.
    Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm. 2002;109:329–39.PubMedGoogle Scholar
  59. 59.
    Mattila PM, Röyttä M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol. 1998;95:576–82.PubMedGoogle Scholar
  60. 60.
    Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain. 2011;134:1493–505.PubMedGoogle Scholar
  61. 61.
    Braak H, Braak E. Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J Neural Transm Park Dis Dement Sect. 1990;2:45–57.PubMedGoogle Scholar
  62. 62.
    Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009;23:295–7.PubMedCentralPubMedGoogle Scholar
  63. 63.
    Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2009;132:2947–57.PubMedGoogle Scholar
  64. 64.
    Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67:1931–4.PubMedGoogle Scholar
  65. 65.
    Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett. 2010;486:19–23.PubMedGoogle Scholar
  66. 66.
    McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050–8.PubMedGoogle Scholar
  67. 67.
    Dickson DW. Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol. 2002;15:210–6.PubMedGoogle Scholar
  68. 68.
    Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol Dis. 2011;41:377–84.PubMedGoogle Scholar
  69. 69.
    Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol. 2012;69:1326–31.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis. 2007;4:428–30.PubMedGoogle Scholar
  71. 71.
    Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331–8.PubMedGoogle Scholar
  72. 72.
    Johansson A, Savitcheva I, Forsberg A, Engler H, Långström B, Nordberg A, et al. [11C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat Disord. 2008;14:345–7.PubMedGoogle Scholar
  73. 73.
    Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34:107–12.PubMedGoogle Scholar
  74. 74.
    Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord. 2010;25:2516–23.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Jokinen P, Scheinin N, Aalto S, Någren K, Savisto N, Parkkola R, et al. [11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord. 2010;16:666–70.PubMedGoogle Scholar
  76. 76.•
    Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012;27:965–73. This article confirmed prior results showing greater PiB retention in DLB compared with PDD and PD and showed that age and apolipoprotein ε4 contribute to PiB burden in Lewy body diseases, as they do in HCS and AD subjects.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology. 2013;38:938–49.PubMedCentralPubMedGoogle Scholar
  78. 78.•
    Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurol. 2014;14:79. Florbetapir and the vesicular monoamine transporter ligand florbenazine were used to differentiate between AD subjects, DLB subjects, PD subjects, and HCS.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Kepe V, Bordelon Y, Boxer A, Huang SC, Liu J, Thiede FC, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis. 2013;36:145–53.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology. 2012;79:1161–7.PubMedCentralPubMedGoogle Scholar
  81. 81.•
    Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80:85–91. This article shows that baseline amyloid burden predicts cognitive decline in PD.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027–33.PubMedGoogle Scholar
  83. 83.•
    Shimada H, Shinotoh H, Hirano S, Miyoshi M, Sato K, Tanaka N, et al. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord. 2013;28:169–75. This article associated amyloid burden in DLB and PDD with medial temporal lobe and cortical atrophy.PubMedGoogle Scholar
  84. 84.
    Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25.PubMedGoogle Scholar
  85. 85.
    Claassen DO, Lowe VJ, Peller PJ, Petersen RC, Josephs KA. Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord. 2011;17:160–5.PubMedGoogle Scholar
  86. 86.•
    Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain. 2011;134:1647–57. PiB and vesicular monoamine transporter imaging of the dopamine terminal were used to differentiate AD, DLB, and FTD subjects with mild dementia.PubMedCentralPubMedGoogle Scholar
  87. 87.•
    Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091–105. This article compared AD and DLB patients using MRI, PiB imaging, and fluorodeoxyglucose imaging; a subset of patients underwent neuropathological evaluation. It found that a single imaging modality did not differentiate groups or individual patients well, but that using at least two modalities improved their discrimination.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Graff-Radford J, Boeve BF, Pedraza O, Ferman TJ, Przybelski S, Lesnick TG, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain. 2012;135:2470–7.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414–21.PubMedGoogle Scholar
  90. 90.•
    Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, et al. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 2012;123:433–47. This article explored the sensitivity of PiB and PiB imaging in a case of DLB with negative PiB imaging findings, and found that in some brain regions Aβ levels were significant, exceeding local plaque density and PiB binding.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77:585–9.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord. 2006;21:1123–30.PubMedGoogle Scholar
  93. 93.•
    Müller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, et al. β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord. 2013;28:296–301. This article reported a relationship between amyloid burden and postural instability in PD with MCI.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, et al. Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013;84:537–43.PubMedGoogle Scholar
  95. 95.
    Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.PubMedGoogle Scholar
  96. 96.•
    Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Alzheimer's Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013;74:826–36. This study found that florbetapir PET findings and CSF levels of Aβ were highly correlated across HCS, MCI subjects, and AD subjects.PubMedGoogle Scholar
  97. 97.
    Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69:1445–52.PubMedGoogle Scholar
  98. 98.
    Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69:570–80.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010;25:2682–5.PubMedCentralPubMedGoogle Scholar
  100. 100.•
    Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055–61. This article shows that the baseline CSF level of Aβ predicts cognitive decline in PD.PubMedCentralPubMedGoogle Scholar
  101. 101.•
    Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, et al. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82:1784–90. This article replicates the result in [100] showing that the baseline CSF level of Aβ predicts cognitive decline in PD.PubMedGoogle Scholar
  102. 102.
    Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology. 2000;54:1875–6.PubMedGoogle Scholar
  103. 103.
    Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain. 2007;130:2607–15.PubMedGoogle Scholar
  104. 104.
    Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O'Keefe G, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology. 2010;74:487–93.PubMedGoogle Scholar
  105. 105.
    McKeith I. Dementia with Lewy bodies. Dialogues Clin Neurosci. 2004;6:333–41.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44:673–83.PubMedGoogle Scholar
  107. 107.
    Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98:12245–50.PubMedCentralPubMedGoogle Scholar
  108. 108.•
    Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med. 2012;16:1166–83. This review discusses synergistic interactions between Aβ, tau, and α-synuclein that could contribute to neurodegeneration in PD and DLB.PubMedGoogle Scholar
  109. 109.•
    Sinha N, Firbank M, O'Brien JT. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry. 2012;27:443–53. This review focuses on biomarkers in DLB.PubMedGoogle Scholar
  110. 110.•
    Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord. 2014;29:622–33. This review discusses biomarkers in PD.PubMedGoogle Scholar
  111. 111.
    Albin RL, Burke JF, Koeppe RA, Giordani B, Gilman S, Frey KA. Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. J Nucl Med. 2013;54:887–93.PubMedCentralPubMedGoogle Scholar
  112. 112.
    Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–22.PubMedGoogle Scholar
  113. 113.
    Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis. 2010;19:573–89.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis. 2012;31:601–12.PubMedGoogle Scholar
  115. 115.
    Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108.PubMedGoogle Scholar
  116. 116.
    Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. J Alzheimers Dis. 2013;34:457–68.PubMedGoogle Scholar
  117. 117.
    Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84.PubMedGoogle Scholar
  118. 118.
    Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014. doi:10.1093/brain/awu064.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.MassGeneral Institute for Neurodegenerative DiseaseCharlestownUSA

Personalised recommendations